-
The Hyderabad-based drug major is voluntarily recalling the affected lots of the drug in 10 mg strength due to “failed impurities degradation specifications”.
-
The drug maker's growth would be primarily driven by organic moves, focusing around pipeline monetisation, productivity enhancement, diversifications.
-
The drug can be added as a supplement or adjunct to the existing treatment protocols to treat moderate to severe Covid patients
-
So far, Dr Reddy’s has received the first consignment of 1.5 lakh doses on May 1 with imported supplies of the first dose.
-
Pilot programme to administer from the first batch of 1,50,000 doses of Sputnik V vaccines imported from RDIF
-
Plan to vaccinate 125 million people in the next 8-12 months across the country
-
For FY21, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20.
-
To manufacture and commercialise baricitinib in India, approved for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults
-
The latest therapy with links to the city is the glucose molecule 2-DG and its anti-Covid-19 therapeutic application that was given a green signal by Indian drug regulatory authorities
-
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO).
-
Hyderabad-based Dr Reddy’s Laboratories has collaborated with RDIF to import the first consignment of Sputnik-V while it is expected that the pharma giant will start manufacturing from its local facilities in India
-
India has become the 60th country to approve Sputnik V, RDIF, Russia's sovereign wealth fund, said in a statement.
-
As part of the review process, the drug major will present the safety profile of phase 2 study, and interim data of phase 3 trial, which is expected to be complete by February 21
-
With a CGT designation, the company has a 180-day CGT exclusivity to market this product, he added.
-
Total revenue from operations stood at Rs 4,929.6 crore for the third quarter, up 12.38 per cent year-on-year
-
The trial will be conducted on 1,500 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India
-
Exploring opportunities for mutual investments and trade in the life sciences sector
-
Trial will be a multicentre, randomised controlled study, which will include safety and immunogenicity
-
The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries.
-
Collaboration will allow Dr Reddy’s to identify and use some of the Biotechnology Industry Research Assistance Council’s clinical trial centres
